STOCK TITAN

111 Inc - YI STOCK NEWS

Welcome to our dedicated news page for 111 (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 111's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 111's position in the market.

Rhea-AI Summary
111, Inc. (YI) announced its unaudited financial results for Q4 and fiscal year 2023, with net revenues of RMB4.1 billion in Q4 and RMB14.9 billion for the year. Despite a decrease in net revenues in Q4, the company saw growth in gross segment profit for the fiscal year. Operating expenses decreased, but losses from operations increased in Q4. The company emphasized operational efficiency improvements and digital innovation in the pharmaceutical sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.26%
Tags
earnings
-
Rhea-AI Summary
111, Inc. (YI) announces the release of its unaudited financial results for Q4 and fiscal year 2023 on March 21, 2024. The company aims to digitally connect patients with healthcare services in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
earnings
-
Rhea-AI Summary
111, Inc. (YI) receives notice of withdrawal of going private proposals from consortium led by company co-founders Dr. Gang Yu and Mr. Junling Liu. Consortium terminates negotiations with special committee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
Rhea-AI Summary
111, Inc. (YI) reported net revenues of RMB3.7 billion, a 9.5% YoY increase, with a gross segment profit of RMB 190.6 million. However, total operating expenses were RMB 271.0 million, resulting in a loss from operations of RMB80.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
earnings
-
Rhea-AI Summary
111, Inc. (NASDAQ: YI) to Report Third Quarter 2023 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
earnings
-
Rhea-AI Summary
111, Inc. reports Q2 2023 financial results with net revenues of RMB3.5 billion, representing a 14.5% YoY increase. Gross segment profit increased by 8.3% YoY. Total operating expenses decreased to 7.2% of net revenues. Loss from operations decreased to RMB41.4 million, down from RMB79.8 million in the same quarter last year. Non-GAAP loss from operations decreased to RMB17.2 million. Net loss decreased to RMB45.4 million, down from RMB84.8 million in the same quarter last year. Cash and cash equivalents as of June 30, 2023, were RMB735.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
earnings
111 Inc

Nasdaq:YI

YI Rankings

YI Stock Data

97.43M
65.94M
16.72%
28.29%
0.06%
Pharmacies and Drug Stores
Retail Trade
Link
China (Mainland)
Shanghai

About YI

111, inc., through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the people's republic of china. it operates through two segments, b2b and b2c. the company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. its product portfolio comprises prescription and over-the counter drugs, such as western and traditional chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. the company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 drug mall, includin